Early Data In Hand, Vesper Bio Takes On GSK And Alector

While a handful of new Alzheimer’s drugs have made it to market in recent years, some groups are working on other forms of dementia. One such is Vesper Bio, whose sortilin inhibitor VES001 generated encouraging Phase I data in frontotemporal dementia earlier this month.

“We’ve shown that we have a safe and well tolerated drug … and we’ve shown that it gets into the brain,” Paul Little, Vesper’s CEO, told Scrip. “We’ve actually demonstrated...